Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-05-29

Recombinant Pharmaceuticals from Plants for Human Health

Ziel

Plants are attractive vehicles for the expression of recombinant pharmaceutical proteins as they are inexpensive and versatile systems, amenable to rapid and economical scale-up. Public opinion in Europe is generally negative towards GM plants, which has led to the loss of many SMEs and commercial development from the Union. However, the use of GM plants for medicines and vaccines rates very highly in terms of public acceptance. With this proposal, our primary aim is to build on previous proof-of-concept studies to develop pharmaceutical products through to clinical trials. The use of GM pharmaceuticals has precedents, such as human insulin and hepatitis B vaccine, but plant-derived materials used in humans has not been formally addressed within the EU. A major outcome will be to define the regulatory requirements through a process of engagement and consultation with all relevant regulatory bodies (involved in GM plants as well as new pharmaceuticals), in order to move through clinical trials and gain permission for the use of plant derived pharmaceuticals in practice. Monoclonal antibodies will be the first generation of molecules to be developed for Phase I clinical evaluation, and we include 2 neutralising antibodies each for HIV and rabies. The proposal also includes a limited range of other targets, against HIV, TB and diabetes, and for some of these, new expression strategies will need to be developed. They represent the second-generation molecules, which will feed the development pipeline for SMEs in Europe, beyond the lifetime of the project. In each case, plant-based systems offer a real advantage, if not the only option for production on a scale relevant to the needs for that molecule. Alongside our principle aim of developing plant derived recombinant pharmaceuticals, we recognise the need to put in place comprehensive risk assessments based on health and environmental impacts, and to work with EU regulatory authorities.

Wissenschaftliches Gebiet (EuroSciVoc)

CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht.

Sie müssen sich anmelden oder registrieren, um diese Funktion zu nutzen

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

FP6-2002-LIFESCIHEALTH
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

IP - Integrated Project

Koordinator

FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
EU-Beitrag
Keine Daten
Adresse
Hansastrasse 27c
MÜNCHEN
Deutschland

Auf der Karte ansehen
Links
Gesamtkosten
Keine Daten

Beteiligte (31)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 20 Dezember 2012

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/503565/de

European Union, 2025